FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sarat Chandarlapaty

Research Profile

Chemicals & Drugs

Anatomy

Tumor Cell Line

Disorders

Breast Neoplasms

Physiology

Procedures

Living Beings

Concepts & Ideas

Tumor Burden

Co-author Network

Publications

TOP 3
Sarat Chandarlapaty; Dilip Giri; Adriana Heguy; Clifford Hudis; Shanu Modi; Monica Morrow; Larry Norton; Sujata Patil; Neal Rosen; Rita A Sakr; Tari A King
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast Cancer.
Piro Lito; Taha Merghoub; Poulikos I Poulikakos; Christine A Pratilas; Margaret K Callahan; Sarat Chandarlapaty; Elisa de Stanchina; James A Fagin; Ensar Halilovic; Alan Huang; Eric W Joseph; Madhavi Tadi; Jedd D Wolchok; Wai Lin Wong; Matthew Zubrowski; Neal Rosen
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Sarat Chandarlapaty
Negative feedback and adaptive resistance to the targeted therapy of cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sarat Chandarlapaty (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sarat Chandarlapaty; Dilip Giri; Adriana Heguy; Clifford Hudis; Shanu Modi; Monica Morrow; Larry Norton; Sujata Patil; Neal Rosen; Rita A Sakr; Tari A King
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(24):6784-91.
2012: Piro Lito; Taha Merghoub; Poulikos I Poulikakos; Christine A Pratilas; Margaret K Callahan; Sarat Chandarlapaty; Elisa de Stanchina; James A Fagin; Ensar Halilovic; Alan Huang; Eric W Joseph; Madhavi Tadi; Jedd D Wolchok; Wai Lin Wong; Matthew Zubrowski; Neal Rosen
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Cancer cell 2012;22(5):668-82.
2012: Sarat Chandarlapaty
Negative feedback and adaptive resistance to the targeted therapy of cancer.
Cancer discovery 2012;2(4):311-9.
2011: Sarat Chandarlapaty; Shanu Modi
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3111-3.
2011: Vanessa S Rodrik-Outmezguine; Maurizio Scaltriti; José Baselga; Sarat Chandarlapaty; Sylvie Guichard; Elizabeth Moskatel; Nen C Pagano; Poulikos I Poulikakos; Neal Rosen
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Cancer discovery 2011;1(3):248-59.
2011: V Serra; M Scaltriti; L Prudkin; P J A Eichhorn; Y H Ibrahim; Sarat Chandarlapaty; B Markman; O Rodriguez; M Guzman; S Rodriguez; M Gili; M Russillo; J L Parra; S Singh; J Arribas; N Rosen; J Baselga
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Oncogene 2011;30(22):2547-57.
2011: Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Cancer cell 2011;19(5):575-86.
2011: Maurizio Scaltriti; Pieter J Eichhorn; Javier Cortés; Ludmila Prudkin; Claudia Aura; José Jiménez; Sarat Chandarlapaty; Violeta Serra; Aleix Prat; Yasir H Ibrahim; Marta Guzmán; Magui Gili; Olga Rodríguez; Sonia Rodríguez; José Pérez; Simon R Green; Sabine Mai; Neal Rosen; Clifford Hudis; José Baselga
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(9):3761-6.
2011: Devika Gajria; Sarat Chandarlapaty
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Expert review of anticancer therapy 2011;11(2):263-75.
2011: Sarat Chandarlapaty; Ayana Sawai; Maurizio Scaltriti; Vanessa Rodrik-Outmezguine; Olivera Grbovic-Huezo; Violeta Serra; Pradip K Majumder; Jose Baselga; Neal Rosen
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Cancer cell 2011;19(1):58-71.
2010: Rita A Sakr; Violetta Barbashina; Mary Morrogh; Sarat Chandarlapaty; Victor P Andrade; Crispinita D Arroyo; Narciso Olvera; Tari A King
Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2010;18(4):371-4.
2010: Maurizio Scaltriti; Sarat Chandarlapaty; Ludmila Prudkin; Claudia Aura; José Jimenez; Pier Davide Angelini; Gertrudis Sánchez; Marta Guzman; Josep Lluis Parra; Catherine Ellis; Robert Gagnon; Maria Koehler; Henry Gomez; Charles Geyer; David Cameron; Joaquín Arribas; Neal Rosen; José Baselga
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(9):2688-95.
2010: Sarat Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; Clifford Hudis; Larry Norton; David B Solit; Joaquín Arribas; José Baselga; Neal Rosen
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Oncogene 2010;29(3):325-34.
2008: Ayana Sawai; Sarat Chandarlapaty; Heidi Greulich; Mithat Gonen; Qing Ye; Carlos L Arteaga; William R Sellers; Neal Rosen; David B Solit
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Cancer research 2008;68(2):589-96.
2008: Qing-Bai She; Sarat Chandarlapaty; Qing Ye; Jose Lobo; Kathleen M Haskell; Karen R Leander; Deborah DeFeo-Jones; Hans E Huber; Neal Rosen
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
PloS one 2008;3(8):e3065.
2008: Sarat Chandarlapaty; Ayana Sawai; Qing Ye; Anisa Scott; Melanie Silinski; Ken Huang; Pat Fadden; Jeff Partdrige; Steven Hall; Paul Steed; Larry Norton; Neal Rosen; David B Solit
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):240-8.
1998: Sarat Chandarlapaty; Beverly Errede
Ash1, a daughter cell-specific protein, is required for pseudohyphal growth of Saccharomyces cerevisiae.
Molecular and cellular biology 1998;18(5):2884-91.